Metronomics Global Health Initiative

3rd Karton Kamen-MGHI Prize : call for abstracts

2017-11-21T08:20:05Z

We are very proud to launch the call for abstract for the Third Barton Kamen-MGHI prize

The prize is given in honor of Pr. Barton Kamen, pediatric oncologist, pioneer in the field of metronomic chemotherapy. Barton Kamen has been one of the leading force that has kept the field of metronomics alive when it was facing resistance/skepticism from clinicians. Barton has also been a source of inspiration for clinical colleagues, scientists and mentored many junior scientists. Barton Kamen was also the first very MGHI ambassador. Through this prize, we wish to acknowledge his critical role for the field of metronomics and maintain his legacy alive by rewarding a clinician or a scientist working in the field of metronomics. Priority will be given to work focusing on children living in low and middle countries

This prize is awarded to the author of the best submitted scientific article. The jury can also propose candidate. The winner will present his work and receive the prize during the 6th Metronomic Meeting that will take place in Grand Rapids in May 2018 (click here for more information) All accepted abstracts will be published on the MGHI website.

The dead-line for submission is 01/03/2018 Results will be given by email before the 10th of April.

For more information conctact: metronomicsghi@gmail.com

Abstract Requirements and Guidelines

Formatting Tips:

Abstracts must be submitted in English by email at metronomicsghi@gmail.com. Each abstract should consist of four separate paragraphs. These should be labeled Background, Methods, Results, and Conclusions. Each abstract should, briefly and concisely, describe the problem or issue being addressed, how the study was performed, the salient results or findings, and what the authors conclude from these results.

Abstracts are not to exceed 200 words, excluding title and authors.The length should correspond to approximately 1 pages, single-spaced, in a Word document Abstract titles are restricted to 25 words.. You will type the title, authors and keywords into individual fields, separately from the body of the abstract.

Abstracts must clearly define the objectives, status, methodology, findings, and significance of the investigation or stud

How Abstracts are Judged and Assigned

Abstracts submitted for presentation will be reviewed by the Scientific Committee in April. Notification of acceptance and schedule information will be sent in APRIL. Abstracts will be judged according to four criteria: scientific merit, originality, interest for metronomic

The 2nd Barton Kamen-MGHI Prize has been attributed to Pr G. Saulnier-Sholler : DFMO in Neuroblastoma

2016-05-09T16:09:37Z

The Second Barton Kamen-MGHI Prize has been attributed to Pr Giselle Saulnier Sholler, during the 5th Metronomic Meeting that took place in Mumbai from the 6th to 8th of MAY 2016. Pr G. SAULINER is currently
Director of Pediatric Oncology Research
Head of the Pediatric Oncology Translational Research Laboratory
Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
Associate Professor, Michigan State University College of Human Medicine
Chair of the Neuroblastoma & Medulloblastoma Translational Research Consortium

The prize was given to her in recognition of her work on DFMO in neuroblastoma.

Read more about DFMO and the NMTCR here.

Second Barton Kamen-MGHI prize: call for abstract

2016-01-27T13:47:32Z

We are very proud to launch the call for abstract for the Second Barton Kamen-MGHI prize

The prize is given in honor of Pr. Barton Kamen, pediatric oncologist, pioneer in the field of metronomic chemotherapy. Barton Kamen has been one of the leading force that has kept the field of metronomics alive when it was facing resistance/skepticism from clinicians. Barton has also been a source of inspiration for clinical colleagues, scientists and mentored many junior scientists. Barton Kamen was also the first very MGHI ambassador. Through this prize, we wish to acknowledge his critical role for the field of metronomics and maintain his legacy alive by rewarding a clinician or a scientist working in the field of metronomics. For the first prize, priority will be given to work focusing on children living in low and middle countries

This prize is awarded to the author of the best submitted scientific article. The winner will present his work and receive the prize during the 5th Metronomic Meeting that will take place in Mumbai in May 2016 (click here for more information) All accepted abstracts will be published on the MGHI website.

The dead-line for submission is 1/04/2016 Results will be given by email before the 10th of April.

For more information conctact : metronomicsghi@gmail.com

Abstract Requirements and Guidelines

Formatting Tips:

Abstracts must clearly define the objectives, status, methodology, findings, and significance of the investigation or stud

How Abstracts are Judged and Assigned

Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential.

2016-01-01T10:32:00Z

Porkholm M, Toiviainen-Salo S, Seuri R, Lönnqvist T, Vepsäläinen K, Saarinen-Pihkala UM, Pentikäinen V, Kivivuori SM from the Division of Hematology-Oncology and Stem Cell Transplantation, the Division of Child Neurology, the Division of Pediatrics and the Department of Pediatric Radiology from the University of Helsinki and Helsinki University Hospital, Helsinki, Finland. have just published an article entitled "Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential." in Acta Paediatrica.

They report on 17 children with refractory or high-risk malignancies who were treated with a maintenance therapy that consisted of metronomic thalidomide, etoposide and celecoxib. The endpoints of the study were overall and progression-free survival, changes in the Karnofsky-Lansky scores from baseline to the end of the study therapy and radiological responses.
The median overall survival after the start of the study therapy was 6.2 months (range 2.0-57.7) and the six, 12 and 24-month survival rates were 59%, 18% and 18%, respectively. The median progression-free survival was 3.2 months (range 0.3-17.8). The Karnofsky-Lansky scores increased significantly during the study therapy (p=0.02), with 35% of the patients having a transient improvement in their clinical status. Radiologically, one partial response and two disease stabilisations were encountered. Grade III-IV adverse events occurred in 76% of the patients.
This report highlight that metronomics can increase the quality of life during palliative care for childhood cancer, but requires careful patient selection to minimise the risk of serious adverse events.

You can access the full text on the website of the journal here

First Barton Kamen-MGHI prize : Modified COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) therapy in poor prognosis pediatric malignant brain tumors

2014-07-18T09:08:00Z

The first Barton Kamen-MGHI Prize has been attributed to Pr Shripad Banavali following the submission of the following abstract. The work will be presented during the 4th Metronomic Meeting that will take place in Milano on the 24th and 25th of June 2014.
Dr Shripad D. Banavali is Professor & Head, Dept. of Medical & Pediatric Oncology
Vice President (India), Asian Cellular Therapy Organization and Coordinator, TMC-Rural Outreach Program in Mumbai

MODIFIED COMBAT (COMBINED ORAL METRONOMIC BIODIFFERENTIATING ANTIANGIOGENIC TREATMENT) THERAPY IN POOR PROGNOSIS PEDIATRIC MALIGNANT BRAIN TUMORS - IS THERE A ROLE?

CHINNASWAMY GIRISH, Prasad Maya, Vora Tushar, Arora Brijesh, Sridhar Eppari, Gupta Tejpal, Moiyadi Ali, Jalali Rakesh, Kukure Purna, Banavali Shripad

Background: The outcome of children with recurrent/high risk malignant brain tumors continues to be poor with conventional modalities of therapy. Metronomic therapy (COMBAT) has been found to be beneficial in many disseminated and aggressive pediatric solid tumors. We evaluated the impact (efficacy and toxicity) of this strategy in children with poor prognosis malignant brain tumors.

Methods: Children deemed to have a poor risk malignant brain tumor (by histology, site, metastatic status) were started on modified COMBAT regimen after completion of conventional therapy. Relapsed high grade tumors were also included. The treatment strategy consisted of the COMBAT regimen which includes low dose temozolomide, etoposide, sodium valproate and 13-cisretinoic acid administered in 12-weekly cycles. All children were followed up at 3 monthly intervals with clinical evaluation and MR imaging.

Results: Thirty four children were started on Modified COMBAT therapy between the year 2010-2013 and 32 were available for evaluation. The median age of the study population is 10 years with a male:female ratio being 2:1. Among the 32 patients, 13(40.6%) had relapsed/progressive medulloblastoma, 7(21.9%) had metastatic/recurrent PNET(supratentorial), 7(21.9%) had recurrent anaplastic ependymoma and 5(15.6%) were diagnosed with diffuse pontine glioma. 23/32 (71%) of patients showed a response(SD/PR/CR) to therapy while 9(28%) of patients continued to progress with no response documented. Toxicity included grade III/IV cytopenia in 2 patients and 1 patient developed myelodysplastic syndrome. Isotretinoin skin toxicity was noted in majority and was manageable with topical interventions. In the final analysis 62.5%(20) of patients had progressed with median time to progression being 9 months (2-44 months) while 37.5%(12) patients had shown a positive sustained response.

Conclusion: The modified COMBAT regimen is a feasible, well tolerated and effective treatment option for children with high risk or metastatic brain tumours. The data is a retrospective analysis and hence a prospective study to evaluate this strategy systematically is warranted.

Barton Kamen-MGHI Prize : call for abstract

2014-01-24T09:49:40Z

We are very proud to launch the call for abstract for the first

Barton Kamen-MGHI prize

The prize is given in honor of Pr. Barton Kamen, pediatric oncologist, pioneer in the field of metronomic chemotherapy. Barton has been one of the leading force that has kept the field of metronomics alive when it was facing resistance/skepticism from clinicians. Barton has also been a source of inspiration for clinical colleagues, scientists and mentored many junior scientists. Barton Kamen was also the first very MGHI ambassador. Through this prize, we wish to acknowledge his critical role for the field of metronomics and maintain his legacy alive by rewarding a clinician or a scientist working in the field of metronomics.
For the first prize, priority will be given to work focusing on children living in low and middle countries

This prize is awarded to the author of the best submitted scientific article. The winner will present his work and receive the prize during the 4th Metronomic Meeting that will take place in Milano in June 2014 (click here for more information)
All accepted abstracts will be published on the MGHI website.

The dead-line for submission is 30/03/2014
Results will be given by email before the 10th of April.

For more information conctact : metronomicsghi@gmail.com

Abstract Requirements and Guidelines

Formatting Tips:

Abstracts mus be submitted in English by email at metronomicsghi@gmail.com.
Each abstract should consist of four separate paragraphs. These should be labeled Background, Methods, Results, and Conclusions. Each abstract should, briefly and concisely, describe the problem or issue being addressed, how the study was performed, the salient results or findings, and what the authors conclude from these results.

Abstracts are not to exceed 200 words, excluding title and authors.The length should correspond to approximately 1 pages, single-spaced, in a Word document
Abstract titles are restricted to 25 words..
You will type the title, authors and keywords into individual fields, separately from the body of the abstract.

Abstracts must clearly define the objectives, status, methodology, findings, and significance of the investigation or stud

How Abstracts are Judged and Assigned